New Chief Scientific Officer for Caris Life Sciences

David Spetzler gains a promotion and takes responsibility for all R&D activities

Caris Life Sciences, a US biotechnology company focused on molecular profiling to fulfill the promise of precision medicine, has promoted David Spetzler to the position of Chief Scientific Officer.

Spetzler, previously Senior Vice President of Research and Development, will assume full responsibility for all research and product development activities. One of his new key priorities will be expanding the company's focus on its Carisome TOP platform, a blood-based profiling technology being studied for its utility in drug development, drug delivery, and the diagnosis, prognosis and theranosis of cancer and other complex diseases.

Spetzler has an MS from the School of Mathematical and Statistical Science in Computational Bioscience, a PhD in Molecular Cellular Biology and an MBA from Arizona State University.

Caris Life Sciences is headquartered in Irving, Texas.

You may also like

Research & Development

OGT launches new SureSeq myeloid fusion panel drive myeloid cancer research

The assay enables users to integrate research techniques with a single, streamlined NGS process, expediting the process
Regulatory

Compact process thermostat for efficient temperature control in the lab

The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Manufacturing

Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies

Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
Research & Development

Abzena launches EpiScreen 2.0 to assist the development of complex biologics and bioconjugates

The updated platform delivers an advanced range of immune response measurements, while also providing information on mechanism-of-action and specificity
Research & Development

COVID-19 still a significant risk for the immunocompromised, study finds

AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Research & Development

N4 Pharma and SRI to target and treat previously unreachable human cells

The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Subscribe now